Rett syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by MECP2 transgene

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Rett syndrome (RTT) is a severe neurodevelopmental disorder often caused by mutations in the Methyl-CpG-binding Protein 2 (MECP2) gene.
• Nonsense mutations, which create premature stop codons, account for a significant portion of RTT cases.
• Nonsense mutation suppressing drugs offer a potential therapeutic strategy by enabling the production of full-length proteins.

Purpose of the Study:

• To investigate the efficacy of a nonsense suppression strategy for Rett syndrome.
• To characterize a novel mouse model (Mecp2(R255X)) with a specific MECP2 nonsense mutation.
• To assess the rescue of RTT-like phenotypes and molecular abnormalities through MECP2 re-expression.

Main Methods:

• Development and characterization of a Mecp2(R255X) knock-in mouse model.
• Genetic introduction of an MECP2 transgene to evaluate rescue of phenotypes and signaling pathways.
• Treatment of Mecp2(R255X) embryonic fibroblasts with gentamicin to assess nonsense suppression efficacy.

Main Results:

• Introduction of an MECP2 transgene in Mecp2(R255X) mice led to near-complete rescue of phenotypic abnormalities.
• MECP2 transgene expression corrected mTORC1 signaling abnormalities observed in other Mecp2 models.
• Gentamicin treatment successfully induced full-length MeCP2 protein expression from the p.R255X mutant allele in vitro.

Conclusions:

• The p.R255X mutation in MECP2 is amenable to therapeutic strategies utilizing nonsense suppression.
• Re-expression of MeCP2 protein can effectively rescue RTT-associated phenotypes and molecular deficits.
• This study provides proof of concept and guidelines for developing nonsense suppression therapies for RTT.